Latest Apollo Projects
a collaboration with Prof Sam Janes, University College London
By Richard Butt
Prof Janes has identified BAP-1 loss-of-function mutations as being key for enhanced treatment of mesothelioma and is pursuing multiple translational therapeutic strategies based on this finding. Apollo and the Prof Janes are therefore developing selective, small molecule inhibitors of BAP-1 as therapeutics for mesothelioma and other tumours for which BAP-1 mutation has proven therapeutically beneficial.
< PREV ITEM | > NEXT ITEM a collaboration with Prof John Trowsdale, University of Cambridge